HUP0202322A3 - A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use - Google Patents

A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use

Info

Publication number
HUP0202322A3
HUP0202322A3 HU0202322A HUP0202322A HUP0202322A3 HU P0202322 A3 HUP0202322 A3 HU P0202322A3 HU 0202322 A HU0202322 A HU 0202322A HU P0202322 A HUP0202322 A HU P0202322A HU P0202322 A3 HUP0202322 A3 HU P0202322A3
Authority
HU
Hungary
Prior art keywords
melagatran
obtaining
pharmaceutical composition
composition containing
crystalline form
Prior art date
Application number
HU0202322A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0202322A2 publication Critical patent/HUP0202322A2/hu
Publication of HUP0202322A3 publication Critical patent/HUP0202322A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HU0202322A 1999-07-02 2000-06-30 A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use HUP0202322A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms

Publications (2)

Publication Number Publication Date
HUP0202322A2 HUP0202322A2 (en) 2002-10-28
HUP0202322A3 true HUP0202322A3 (en) 2003-04-28

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202322A HUP0202322A3 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use

Country Status (33)

Country Link
US (1) US6479078B1 (hu)
EP (1) EP1196431B1 (hu)
JP (1) JP2003503508A (hu)
KR (1) KR20020020765A (hu)
CN (1) CN100537598C (hu)
AR (1) AR035553A1 (hu)
AT (1) ATE339438T1 (hu)
AU (1) AU765614B2 (hu)
BR (1) BR0012035A (hu)
CA (1) CA2376944A1 (hu)
CY (1) CY1107542T1 (hu)
CZ (1) CZ20014722A3 (hu)
DE (1) DE60030723T2 (hu)
DK (1) DK1196431T3 (hu)
EE (1) EE200100646A (hu)
ES (1) ES2270849T3 (hu)
HK (1) HK1045529B (hu)
HU (1) HUP0202322A3 (hu)
IL (1) IL146972A0 (hu)
IS (1) IS6215A (hu)
MX (1) MXPA01013441A (hu)
MY (1) MY122760A (hu)
NO (1) NO20016419L (hu)
NZ (1) NZ516187A (hu)
PL (1) PL352872A1 (hu)
PT (1) PT1196431E (hu)
RU (1) RU2243973C2 (hu)
SE (1) SE9902550D0 (hu)
SK (1) SK18832001A3 (hu)
TR (1) TR200103855T2 (hu)
TW (1) TWI250991B (hu)
WO (1) WO2001002426A1 (hu)
ZA (1) ZA200109944B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
CA2547625C (en) * 2003-11-27 2012-07-24 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives and production methods thereof
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
HUP0202322A2 (en) 2002-10-28
NO20016419L (no) 2002-03-01
RU2243973C2 (ru) 2005-01-10
SE9902550D0 (sv) 1999-07-02
DE60030723D1 (de) 2006-10-26
NO20016419D0 (no) 2001-12-28
JP2003503508A (ja) 2003-01-28
EE200100646A (et) 2003-02-17
MXPA01013441A (es) 2002-07-02
KR20020020765A (ko) 2002-03-15
CY1107542T1 (el) 2013-03-13
TWI250991B (en) 2006-03-11
ATE339438T1 (de) 2006-10-15
WO2001002426A1 (en) 2001-01-11
US6479078B1 (en) 2002-11-12
PT1196431E (pt) 2007-01-31
EP1196431B1 (en) 2006-09-13
HK1045529B (zh) 2007-02-23
AU765614B2 (en) 2003-09-25
ES2270849T3 (es) 2007-04-16
IL146972A0 (en) 2002-08-14
DE60030723T2 (de) 2007-11-08
IS6215A (is) 2001-12-27
AU6040800A (en) 2001-01-22
CZ20014722A3 (cs) 2002-05-15
CN100537598C (zh) 2009-09-09
BR0012035A (pt) 2002-03-19
PL352872A1 (en) 2003-09-08
MY122760A (en) 2006-05-31
CA2376944A1 (en) 2001-01-11
DK1196431T3 (da) 2006-12-11
SK18832001A3 (sk) 2002-10-08
ZA200109944B (en) 2003-03-03
AR035553A1 (es) 2004-06-16
CN1359389A (zh) 2002-07-17
NZ516187A (en) 2004-09-24
HK1045529A1 (en) 2002-11-29
EP1196431A1 (en) 2002-04-17
TR200103855T2 (tr) 2002-04-22

Similar Documents

Publication Publication Date Title
EG24142A (en) Crystalline monohydrate, process for the preparation thereof and the use thereof for preparing a pharmaceutical composition
HUP0203183A3 (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use
HUP0203669A3 (en) Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0201376A2 (en) Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301802A3 (en) Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
HUP0203136A3 (en) Piperazine compounds, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105108A3 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0002843A3 (en) New betha-carboline compounds, a process for their preparation and pharmaceutical compositions containing them
HUP0200881A3 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0201516A2 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A2 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203060A3 (en) Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0202876A3 (en) Carboxypeptidase u inhibiting new compounds, process for their preparation and pharmaceutical compositions containing them and their use
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0204069A3 (en) Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202322A2 (en) A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees